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AbstrACt
Introduction Preliminary evidence supports the beneficial 
role of physical activity on prostate cancer outcomes. This 
phase III randomised controlled trial (RCT) is designed to 
determine if supervised high-intensity aerobic and resistance 
exercise increases overall survival (OS) in patients with 
metastatic castrate-resistant prostate cancer (mCRPC).
Methods and analysis Participants (n=866) must have 
histologically documented metastatic prostate cancer with 
evidence of progressive disease on androgen deprivation 
therapy (defined as mCRPC). Patients can be treatment-
naïve for mCRPC or on first-line androgen receptor-targeted 
therapy for mCRPC (ie, abiraterone or enzalutamide) without 
evidence of progression at enrolment, and with no prior 
chemotherapy for mCRPC. Patients will receive psychosocial 
support and will be randomly assigned (1:1) to either 
supervised exercise (high-intensity aerobic and resistance 
training) or self-directed exercise (provision of guidelines), 
stratified by treatment status and site. Exercise prescriptions 
will be tailored to each participant’s fitness and morbidities. 
The primary endpoint is OS. Secondary endpoints include 
time to disease progression, occurrence of a skeletal-related 
event or progression of pain, and degree of pain, opiate 
use, physical and emotional quality of life, and changes in 
metabolic biomarkers. An assessment of whether immune 
function, inflammation, dysregulation of insulin and energy 
metabolism, and androgen biomarkers are associated 
with OS will be performed, and whether they mediate the 
primary association between exercise and OS will also be 
investigated. This study will also establish a biobank for future 
biomarker discovery or validation.
Ethics and dissemination Validation of exercise as 
medicine and its mechanisms of action will create evidence 
to change clinical practice. Accordingly, outcomes of this RCT 
will be published in international, peer-reviewed journals, and 
presented at national and international conferences. Ethics 
approval was first obtained at Edith Cowan University (ID: 
13236 NEWTON), with a further 10 investigator sites since 
receiving ethics approval, prior to activation.
trial registration number NCT02730338.
IntroduCtIon
An emerging body of literature supports the 
role of exercise during cancer treatment as a 
therapy which leads to improved outcomes, 
both in quality of life and potentially 
disease control.1 Identifying and evaluating 
strengths and limitations of this study
 ► This is the first randomised controlled trial (RCT) to 
examine exercise and overall survival in men with 
prostate cancer.
 ► This is a novel multinational, multicentre and mul-
tidisciplinary RCT with 24 months of supervised 
tapered to self-managed exercise with behavioural 
and psychosocial support, compared with self-di-
rected exercise with psychosocial support alone, 
in men with metastatic castrate-resistant prostate 
cancer (mCRPC).
 ► The study proposed will determine the efficacy of 
an individually tailored, progressive and autoregu-
lated aerobic and resistance exercise programme, 
supervised by accredited exercise physiologists 
(or equivalent) in addition to usual medical care, in 
parallel with a health economics analysis to assess 
the health benefits, additional costs and potential 
savings of including exercise therapy as standard of 
care for men with mCRPC.
 ► The study has a translational team to investigate 
biomarkers associated with three candidate path-
ways: systemic inflammation, insulin/glucose me-
tabolism and androgen biosynthesis; to study how 
they mediate the association between exercise and 
overall survival; and to establish a blood, urine and 
tissue biobank for future biomarker discovery or 
validation.
 ► The outcomes of this phase III RCT are limited to 
men with mCRPC.
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low-toxicity adjuvant interventions, such as exercise, 
that can be combined with standard therapy to improve 
outcomes for men with prostate cancer is a high priority 
and has the potential to have a large impact on the clin-
ical and public health burden of prostate cancer.
In 2006, Galvão et al2 reported that resistance exercise 
and programmes with resistance and aerobic exercise 
improved physical function and the quality of life in men 
without metastases on androgen deprivation therapy 
(ADT) for prostate cancer. These results were expanded 
in a subsequent report. Galvão et al3 showed that combined 
resistance and aerobic exercise reversed the loss of 
muscle mass and improved the quality of life in patients 
with prostate cancer on ADT. In addition, Kenfield et al4 
reported that vigorous aerobic exercise after prostate 
cancer diagnosis was associated with a 60% lower risk of 
fatal prostate cancer and a 49% lower risk of all-cause 
mortality among men initially diagnosed with localised 
disease. The dose-specific effect of larger quantities of 
vigorous physical activity having greater survival benefit 
has also been reported by Friedenreich et al.5 In addition, 
one prospective study reported that resistance exercise 
was associated with a 33% lower risk of all-cause mortality 
in male and female cancer survivors while overall physical 
activity was not.6 These findings emphasise the potential 
benefits of exercise as an adjuvant treatment in prostate 
cancer. However, data on exercise and cancer survival to 
date have been from observational studies in which bias 
from confounding and reverse causation are of concern. 
Thus, a randomised controlled trial (RCT) is needed 
to test whether exercise, in particular higher intensity 
aerobic exercise and resistance exercise, impacts overall 
survival (OS) in men with prostate cancer. Additionally, 
treatment-related fatigue is a common side effect in men 
with advanced prostate cancer, and exercise may decrease 
fatigue and increase adherence to treatment regimens.7–9
While the prevailing view among patients and clinicians 
has been that exercise may be problematic for patients 
with cancer with advanced disease, recent research has 
demonstrated tailored resistance and aerobic exercise to 
be well tolerated, safe and effective for improving phys-
ical structure and function.10 Moreover, in patients with 
bone metastases, a highly tailored exercise prescription 
implementing a modular, multimodal approach and 
avoiding excessive loading of the skeletal lesions has been 
demonstrated to be safe and effective.10
There are many potential mechanisms by which exer-
cise may lower risk of prostate cancer progression.1 11 12 
Exercise influences all hormonal systems in the body, 
including key hormones relevant to prostate cancer, 
such as testosterone, growth hormone, insulin and insu-
lin-like growth factor-1 (IGF-1). The androgen receptor 
(AR) and its transactivation by ligand are among the 
most important determinants of prostate cancer progres-
sion. Measurements of serum androgens (including its 
receptors and binding proteins) provide an important 
biomarker for the effectiveness of androgen deprivation 
and prostate cancer progression. The effects of exercise 
on serum androgen levels remain elusive to date,13 
with current studies limited by low patient numbers 
and inadequate methods for measuring testosterone 
levels in the low ranges seen in men on ADT.14 This is 
especially true with the newer cyp17 inhibitors, such as 
abiraterone. Additionally, high levels of inflammatory 
biomarkers are associated with an increased risk of pros-
tate cancer-specific mortality,15 and exercise is known 
to lower levels of circulating inflammatory biomarkers 
(eg, interleukin (IL)-6) in elderly populations.16 17 
Increased physical activity may also produce epigenetic 
modulations that may inhibit tumour cell proliferation, 
such as altering histone deacetylase pathways. Exercise 
and dietary changes may also lower cholesterol, which 
epidemiological studies have suggested are associated 
with decreased risk of prostate cancer and progression of 
prostate cancer.18 19 Together, these observations suggest 
that exercise interventions with patients with prostate 
cancer may improve disease outcomes and quality of life. 
However, given the highly suggestive observational find-
ings, an RCT is warranted to establish clear causal rela-
tionships and guide clinical recommendations.
The primary objective of the GAP4 Intense Exercise for 
Survival among Men with Metastatic Castrate-Resistant 
Prostate Cancer (INTERVAL-GAP4) study is to deter-
mine if high-intensity aerobic and resistance training 
plus psychosocial support increases OS compared with 
self-directed exercise (non-supervised exercise recom-
mendations) plus psychosocial support, in patients with 
metastatic castrate-resistant prostate cancer (mCRPC). 
OS was chosen as the primary endpoint because it has 
clear biological, clinical and public health significance 
and is a validated endpoint for approval of new treat-
ments among men with mCRPC. Additionally, OS data 
can be obtained with minimal loss to follow-up through 
review of medical and death records.
The secondary objectives are to compare time to disease 
progression, time to first occurrence of a symptomatic 
skeletal-related event (SSE), time to progression of pain, 
degree of pain, opiate use, physical and emotional quality 
of life, and change in levels of biomarkers of inflammation, 
energy metabolism and androgen metabolism between 
the supervised exercise and self-directed exercise groups. 
It will also be determined as to whether biomarkers of 
immune function, inflammation, energy metabolism and 
androgen metabolism are associated with OS among men 
with mCRPC, and the extent to which these biomarkers 
mediate the hypothesised association between high-inten-
sity aerobic and resistance exercise and survival will be 
explored.
We hypothesise that men with mCRPC randomised to 
the supervised exercise arm will experience longer OS 
and time to disease progression, less SSE and progres-
sion of pain, less pain and opiate use, better physical 
function and quality of life, and more favourable levels 
of inflammatory, energy metabolism and other metabolic 
biomarkers compared with those in the self-directed exer-
cise arm.
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MEthods
study design
This is a multinational and multicentred, randomised 
controlled phase III clinical trial (INTERVAL-GAP4) 
recruiting 866 men with mCRPC to determine if super-
vised high-intensity aerobic and resistance training with 
psychosocial support increases OS compared with printed 
exercise recommendations (self-directed exercise) with 
psychosocial support. Patients will be randomly assigned 
(1:1) to either supervised exercise or self-directed exer-
cise following the provision of written informed consent, 
confirmation of clinical eligibility and successful comple-
tion of screening assessments (figure 1). This programme 
design has been chosen as it would be unethical to ask 
men with advanced prostate cancer to abstain from exer-
cise for a 2-year period, owing to the documented health 
benefits of exercise in patients with prostate cancer with 
early-stage disease. Accordingly, men randomised to the 
Figure 1 Schematic overview of the INTERVAL-GAP4 trial. 1RM, one-repetition maximum; ACSM, American College of Sports 
Medicine; CPET, cardiopulmonary exercise test; ECG, echocardiogram; INTERVAL-GAP4, Intense Exercise for Survival among 
Men with Metastatic Castrate-Resistant Prostate Cancer, Global Action Plan 4. 
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control arm are free to engage in exercise under their 
own management (self-directed exercise), where changes 
in physical activity of both groups will be monitored.
The trial was prospectively registered on 10 March 2016 
(https:// clinicaltrials. gov/ ct2/ show/ NCT02730338), 
prior to patient recruitment commencing, with the trial 
now recruiting.
Participants
Men with histologically documented adenocarcinoma of 
the prostate and progressive systemic metastatic disease 
despite castrate levels of testosterone (<50 ng/dL) due to 
orchiectomy or luteinising hormone releasing hormone 
(LHRH) agonist (defined as mCRPC), and who meet 
study inclusion (box 1) and exclusion (box 2) criteria 
will be recruited to the study. This patient population was 
chosen because the median OS among men with mCRPC 
is 329 to 358 months; thus, OS is a feasible outcome to 
examine within the budget and timeline of the proposed 
study when using patients with mCRPC as the target 
population. At enrolment, patients can be either treat-
ment-naïve for mCRPC or on first-line AR-targeted 
therapy for mCRPC (ie, abiraterone or enzalutamide) 
without evidence of progression. Patients will be required 
to remain on ADT with a GnRH agonist/antagonist for 
the duration of their involvement in the study or have 
had prior bilateral orchiectomy. At enrolment, patients 
may have received chemotherapy for hormone-sensi-
tive stages of the disease. Patients cannot have received 
chemotherapy for castrate-resistance status at enrolment. 
Patients are not permitted to be on any experimental 
therapies at enrolment; however, patients may be treated 
with chemotherapy or any other therapies for mCRPC 
postenrolment and randomisation.
screening
Once referred to the trial through patients’ managing 
clinician, and consented to the trial by an independent 
research officer, patients will undergo a screening process 
to confirm eligibility, with baseline measures taken prior 
to randomisation and completion of baseline exercise 
testing, if eligible. Measures necessary to complete the 
multivariable nomogram (ht tp:/ /www.canc er.d uke. edu/ 
Nomo gram/ firstlin echemot herapy. html)20 risk assess-
ment are mandatory, including the presence of nodal, 
bone and/or visceral metastases; the use of opioid analge-
sics; Eastern Cooperative Oncology Group performance 
status (must be ≤1); and the collection of standard-of-
care pathology (lactate dehydrogenase (LDH), albumin, 
haemoglobin, alkaline phosphatase (ALP), prostate-spe-
cific antigen) within 28 days prior to baseline assessments. 
Patients must have a Halabi nomogram risk of low or 
intermediate (<195)20 to confirm clinical eligibility prior 
to attempting a symptom-limited, medically supervised 
cardiopulmonary exercise test (CPET) with echocardio-
gram (ECG) recording.
Patients who are currently participating in vigorous 
aerobic activity (>60 min per week) and/or structured 
resistance training (≥2 days per week) will be excluded. 
Patients must have no known contraindications to high-in-
tensity aerobic or resistance exercise as determined by 
box 1 Inclusion criteria
 ► Histologically documented adenocarcinoma of the prostate with 
progressive systemic metastatic disease, despite castrate levels of 
testosterone (<50 ng/dL). Castrate levels of testosterone must be 
maintained while on study.
 ► At enrolment, patients may be clinically eligible through two 
pathways:
 – Pathway A: currently on abiraterone and/or enzalutamide and not 
progressing.
 – Pathway B: preabiraterone and pre-enzalutamide with progres-
sive disease.
 ► Progressive disease must be demonstrated by one or more of the 
following criteria:
1. Measurable disease progression:
 – >20% increase in the sum of diameters of measurable lesions 
from the time of maximal regression; or the appearance of 
one or more new nodal, visceral or skeletal lesions.
2. Bone scan progression:
 – Appearance of one or more new lesions on a bone scan that is 
attributable to prostate cancer.
3. Prostate-specific antigen (PSA) progression:
 – PSA≥2 ng/mL that has risen serially on at least two occasions, 
each at least 1 week apart (PSA1<PSA2<PSA3).
 ► Patients must be on androgen deprivation therapy (ADT) with a 
gonadotropin-releasing hormine (GnRH) agonist/antagonist or prior 
bilateral orchiectomy. All patients are required to be on ADT during 
the study period.
 ► Receive a Halabi nomogram score <195,20 classified as low or in-
termediate risk.
 ► Eastern Cooperative Oncology Group performance status score ≤1.
 ► Age ≥18 years.
 ► Be willing to travel to one of the exercise facilities for exercise test-
ing and training.
 ► Be willing to use the technological aspects of the trial for patient 
monitoring and support.
 ► Fluent in the language designated by the institution where the pa-
tient will be enrolled.
 ► No major surgery ≤4 weeks at enrolment and fully recovered from 
any prior surgery.
 ► Medical clearance to complete a symptom-limited cardiopulmonary 
exercise test (CPET) with electrocardiography, and to complete a 
structured and progressive resistance and aerobic exercise pro-
gramme of moderate-to-vigorous intensity.
 ► Must pass the CPET performed at screening (pre-enrolment), judged 
as achieving a rating of perceived exertion ≥9 on the 10-point Borg 
Scale with no detected cardiac abnormalities. Patients with any ab-
normalities noted are permitted to enrol following cardiologist re-
view and clearance.
 ► Meet the required baseline laboratory values: absolute neutrophil count 
(ANC)≥1.5×109/L (≥1500/μL); platelet count≥100x109/L (≥100 000/
μL); creatinine≤1.5× upper limits of normal; bilirubin≤1.5× upper lim-
its of normal; aspartate aminotransferase (AST)≤1.5× upper limits of 
normal; and serum testosterone≤50 ng/dL.
 ► Patients with bone metastases must be cleared by the Exercise 
Coordination Centre following review of their most recent bone scan 
to ensure they are able to participate in most exercises required by 
the trial.
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their physicians. Following medical clearance, patients 
will be required to complete a series of baseline ques-
tionnaires and will attempt the symptom-limited CPET 
with ECG using a stationary, electronically braked cycle 
ergometer. Patients who successfully pass their CPET 
(ie, no cardiac abnormalities while achieving a maximal 
rating of perceived exertion (RPE ≥9 of the 10-point Borg 
Scale)) will have their study information reviewed by 
the Exercise Coordination Centre (ECC; Edith Cowan 
University, Perth, Australia) for suitability of exercise 
prescription within the INTERVAL-GAP4 programme, 
with consideration given to the location, number and 
severity of bone metastases; and the Study Coordina-
tion Centre (SCC; University of California San Fran-
cisco (UCSF), California, USA) to confirm all clinical and 
study eligibility requirements prior to randomisation and 
subsequent baseline testing.
randomisation
Patients will be centrally randomised by the SCC in a ratio 
of 1:1 to the two study arms, using block randomisation 
in random blocks of 2, 4 and 6, and stratified by site and 
treatment status (ie, abiraterone or enzalutamide, yes/no; 
and radium-223, yes/no) as these therapies have a proven 
effect on progression-free survival.8 9 A research officer at 
the SCC with no patient contact will be responsible for 
uploading the randomisation schedule into the Research 
Electronic Data Capture (REDCap; a secure application 
for building and managing online surveys and data-
bases). Site-based research coordinators will subsequently 
randomise patients through the REDCap system once 
approval from the SCC is received. Patients will not be 
informed of their group allocation until after the comple-
tion of their baseline visit to maintain the integrity of effort 
and the results of assessments performed. At the baseline 
visit, participants will complete all remaining assessments 
including physical function tests (ie, strength tests and 
400 m walk test), fasting blood and first-void urine collec-
tion (ie, for correlative studies and biorepository storage), 
and any remaining questionnaires. Patients randomised to 
the supervised exercise arm will be enrolled into an auto-
mated text messaging programme to provide behavioural 
support, and participants in both arms will commence an 
automated newsletter education programme, circulated at 
the beginning of each cycle, intended to provide psycho-
social support and enhance quality of life.
outcomes
Measurements
This trial comprised a 96-week on-treatment period, 
approximating 2 years (24 cycles with each cycle spanning 
28 days), followed by a 3-year follow-up period. Assess-
ments are conducted at baseline and at routine intervals 
throughout the on-treatment period (table 1). After the 
on-treatment phase ends, patients will enter the follow-up 
phase of the trial, where their medical records and 
death certificates will be reviewed quarterly to quantify 
the primary endpoint of OS and prespecified secondary 
endpoints.
Primary endpoint
Overall survival
OS is the primary outcome of this RCT. It is a validated 
endpoint for the approval of new treatments in medi-
cine, and feasible within the budget and timeline of 
the study as men with mCRPC have a median survival 
of 32–35 months.8 9 Patients will be followed for death a 
minimum of 36 months after randomisation. OS will be 
measured from the time of randomisation until death. 
Medical records and death certificates will be reviewed 
every 3 months to obtain survival status. Country-specific 
mortality databases will also be searched annually; cause 
of death will be determined through review of medical 
and death records. Importantly, quantification of OS 
through review of medical records and death certificates 
reduces loss to follow-up and missing data.
secondary endpoints
Disease progression
Disease progression will be examined through review of 
patient medical records every six cycles and measured 
box 2 Exclusion criteria
 ► No previous progression while on treatment with abiraterone and/
or enzalutamide.
 ► No prior chemotherapy for metastatic castrate-resistant prostate 
cancer.
 ► Not currently receiving experimental treatment with non-approved 
drugs at enrolment.
 ► No known brain metastases.
 ► No known spinal cord compression, compromise or instrumentation 
due to metastatic disease. Radiation therapy for metastatic disease 
is allowed.
 ► No moderate to severe bone pain (Common Terminology Criteria 
for Adverse Events (CTCAE) V.5.0 grading criteria).
 ► No history of hypertension that is not well controlled.
 ► No congestive heart failure.
 ► No recent serious cardiovascular events (within 12 months), includ-
ing but not limited to, transient ischaemic attack, cerebrovascular 
accident or myocardial infarction.
 ► No medical condition, such as uncontrolled infection or cardiac dis-
ease, which in the opinion of the relevant physician would make this 
protocol unreasonably hazardous for the patient.
 ► No serious or non-healing wound, ulcer or bone fracture.
 ► Not experiencing shortness of breath, chest discomfort or palpita-
tions when performing activities of daily living.
 ► Does not have chest pain generated by physical activity and has not 
developed chest pain in the previous month.
 ► No peripheral neuropathy grade ≥3 (CTCAE V.5.0 grading criteria).
 ► No psychiatric illness.
 ► No small cell neuroendocrine tumours or pure small cell carcinoma 
of the prostate.
 ► No current active second malignancy other than non-melanoma 
skin cancer.
 ► Not participating in vigorous aerobic exercise for more than 60 min 
per week.
 ► Not participating in structured resistance exercise for ≥2 sessions 
per week.
6 Newton RU, et al. BMJ Open 2018;8:e022899. doi:10.1136/bmjopen-2018-022899
Open Access 
Ta
b
le
 1
 
S
um
m
ar
y 
of
 IN
TE
R
VA
L-
G
A
P
4 
as
se
ss
m
en
ts
S
cr
ee
ni
ng
O
n-
tr
ea
tm
en
t 
st
ud
y 
p
er
io
d
 (e
ac
h 
cy
cl
e=
28
 d
ay
s)
O
ff
-
tr
ea
tm
en
t
C
yc
le
 0
: 
b
as
el
in
e
S
up
er
vi
se
d
 e
xe
rc
is
e
Tr
an
si
ti
o
n
S
el
f-
m
an
ag
ed
 e
xe
rc
is
e 
p
ro
g
ra
m
m
e
Fo
llo
w
-u
p
 
p
er
io
d
 
   C
yc
le
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
 
   In
fo
rm
ed
 c
on
se
nt
X
 
   R
an
d
om
is
at
io
n
X
C
lin
ic
al
 h
is
to
ry
 
   M
ed
ic
al
 h
is
to
ry
*
X
X
 
   M
ed
ic
at
io
n/
tr
ea
tm
en
t 
hi
st
or
y
X
X
X
X
X
X
X
X
X
B
od
y 
m
ea
su
re
m
en
ts
 
   W
ei
gh
t,
 w
ai
st
, h
ip
 c
irc
um
fe
re
nc
e,
 
he
ig
ht
 (a
t 
b
as
el
in
e 
on
ly
)
X
X
X
X
X
La
b
 s
tu
d
ie
s
 
   C
B
C
 w
/d
iff
, b
lo
od
 c
he
m
is
tr
ie
s
X
X
X
 
   Fa
st
in
g 
lip
id
 p
ro
fil
e,
 fa
st
in
g 
gl
uc
os
e,
 h
ae
m
og
lo
b
in
 A
1c
X
X
E
ffi
ca
cy
 
   O
ve
ra
ll 
su
rv
iv
al
, d
is
ea
se
 
p
ro
gr
es
si
on
, s
ym
p
to
m
at
ic
-
sk
el
et
al
 e
ve
nt
† 
X
X
X
X
Tw
ic
e 
ye
ar
ly
 
   W
H
O
 A
na
lg
es
ic
 S
ca
le
X
X
X
X
X
X
X
X
X
O
nc
e 
ye
ar
ly
 
   E
xe
rc
is
e 
te
st
in
g—
su
p
er
vi
se
d
 a
rm
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
 
   E
xe
rc
is
e 
te
st
in
g—
se
lf-
d
ire
ct
ed
 
ar
m
X
X
X
X
X
S
af
et
y
 
   M
ed
ic
al
 c
le
ar
an
ce
X
X
X
X
X
 
   V
ita
l s
ig
ns
X
X
X
X
X
X
 
   E
C
O
G
 p
er
fo
rm
an
ce
 s
ta
tu
s
X
X
X
X
X
X
X
X
X
 
   B
on
e 
p
ai
n 
at
 e
xe
rc
is
e 
vi
si
ts
A
ss
es
se
d
 a
t 
ea
ch
 s
up
er
vi
se
d
 e
xe
rc
is
e 
vi
si
t 
us
in
g 
VA
S
 
   A
d
ve
rs
e 
ev
en
ts
‡
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
 
   C
on
co
m
ita
nt
 m
ed
ic
at
io
ns
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
M
et
ab
ol
ic
 r
es
ea
rc
h 
st
ud
ie
s
 
   R
es
ea
rc
h 
b
lo
od
 (f
as
tin
g)
X
X
X
X
 
   FF
P
E
 t
um
ou
r 
sp
ec
im
en
s
R
eq
ue
st
 
   U
rin
e 
sp
ec
im
en
s
X
X
X
X
C
on
tin
ue
d
7Newton RU, et al. BMJ Open 2018;8:e022899. doi:10.1136/bmjopen-2018-022899
Open Access
S
cr
ee
ni
ng
O
n-
tr
ea
tm
en
t 
st
ud
y 
p
er
io
d
 (e
ac
h 
cy
cl
e=
28
 d
ay
s)
O
ff
-
tr
ea
tm
en
t
C
yc
le
 0
: 
b
as
el
in
e
S
up
er
vi
se
d
 e
xe
rc
is
e
Tr
an
si
ti
o
n
S
el
f-
m
an
ag
ed
 e
xe
rc
is
e 
p
ro
g
ra
m
m
e
Fo
llo
w
-u
p
 
p
er
io
d
P
at
ie
nt
-r
ep
or
te
d
 o
ut
co
m
es
 
   D
em
og
ra
p
hi
cs
 a
nd
 h
ea
lth
 h
is
to
ry
 
q
ue
st
io
nn
ai
re
X
 
   E
xe
rc
is
e 
sc
re
en
in
g 
q
ue
st
io
nn
ai
re
X
 
   E
xe
rc
is
e,
 q
ua
lit
y 
of
 li
fe
 a
nd
 
m
em
or
y 
q
ue
st
io
nn
ai
re
s 
(3
-m
on
th
 
or
 6
-m
on
th
 in
te
rv
al
s,
 d
ep
en
d
in
g 
on
 s
ur
ve
y)
X
X
X
X
X
X
X
X
X
X
§
 
   Fo
od
 F
re
q
ue
nc
y 
Q
ue
st
io
nn
ai
re
X
X
X
*N
ew
 c
on
d
iti
on
s 
d
ia
gn
os
ed
 o
n-
st
ud
y 
ar
e 
re
co
rd
ed
 d
ur
in
g 
th
e 
on
-s
tu
d
y 
p
er
io
d
.
†P
er
 r
ev
ie
w
 o
f m
ed
ic
al
 r
ec
or
d
s 
or
 o
th
er
 d
oc
um
en
ta
tio
n.
 M
or
ta
lit
y 
d
at
a 
w
ill
 b
e 
co
lle
ct
ed
 t
hr
ou
gh
 m
ed
ic
al
 r
ec
or
d
s,
 d
ea
th
 r
ec
or
d
s 
an
d
 o
th
er
 r
es
ou
rc
es
 e
ve
ry
 6
 m
on
th
s 
d
ur
in
g 
th
e 
on
-t
re
at
m
en
t 
an
d
 fo
llo
w
-u
p
 p
er
io
d
s.
 If
 t
he
 p
ar
tic
ip
an
t 
is
 lo
st
 t
o 
fo
llo
w
-u
p
, w
e 
w
ill
 c
on
ta
ct
 n
ex
t 
of
 k
in
 o
r 
al
te
rn
at
e 
co
nt
ac
t.
 D
ea
th
 c
er
tifi
ca
te
s 
w
ill
 a
ls
o 
b
e 
re
q
ue
st
ed
 a
nd
 a
ll 
m
ed
ic
al
 in
fo
rm
at
io
n 
p
er
ta
in
in
g 
to
 
th
e 
d
ea
th
 w
ill
 b
e 
ce
nt
ra
lly
 r
ev
ie
w
ed
 t
o 
d
et
er
m
in
e 
ca
us
e 
of
 d
ea
th
.
‡C
on
tin
uo
us
ly
 r
ep
or
te
d
 fr
om
 in
fo
rm
ed
 c
on
se
nt
 u
nt
il 
28
 d
ay
s 
af
te
r 
cy
cl
e 
24
, d
ay
 1
.
§S
el
ec
te
d
 a
ss
es
sm
en
ts
 w
ill
 b
e 
ad
m
in
is
te
re
d
 d
ur
in
g 
th
e 
fo
llo
w
-u
p
 p
er
io
d
 o
n 
a 
ye
ar
ly
 b
as
is
. I
f n
o 
re
sp
on
se
 is
 r
ec
ei
ve
d
 fr
om
 t
he
 p
ar
tic
ip
an
t 
an
d
 m
ed
ic
al
 r
ec
or
d
s 
d
o 
no
t 
in
d
ic
at
e 
d
ea
th
, w
e 
w
ill
 
fo
llo
w
 u
p
 w
ith
 n
ex
t 
of
 k
in
 o
r 
al
te
rn
at
e 
co
nt
ac
t.
C
B
C
, C
om
p
le
te
 B
lo
od
 C
ou
nt
; W
H
O
, W
or
ld
 H
ea
lth
 O
rg
an
is
at
io
n;
 V
A
S
, V
is
ua
l A
na
lo
g 
S
ca
le
; E
C
O
G
, E
as
te
rn
 C
oo
p
er
at
iv
e 
O
nc
ol
og
y 
G
ro
up
; F
FP
E
, f
or
m
al
in
-fi
xe
d
 p
ar
af
fin
-e
m
b
ed
d
ed
; I
N
TE
R
VA
L-
G
A
P
4,
 In
te
ns
e 
E
xe
rc
is
e 
fo
r 
S
ur
vi
va
l a
m
on
g 
M
en
 w
ith
 M
et
as
ta
tic
 C
as
tr
at
e-
R
es
is
ta
nt
 P
ro
st
at
e 
C
an
ce
r 
- 
G
lo
b
al
 A
ct
io
n 
P
la
n 
4
Ta
b
le
 1
 
C
on
tin
ue
d
 
8 Newton RU, et al. BMJ Open 2018;8:e022899. doi:10.1136/bmjopen-2018-022899
Open Access 
by the treating physician based on the Prostate Cancer 
Trials Working Group 3 (PCWG-3)21 and Response Eval-
uation Criteria in Solid Tumours (RECIST) 1.122 criteria 
to determine and monitor specific indications of disease 
progression (table 2). Time to disease progression will 
be measured from randomisation until the first of the 
following: first CT or bone scan documenting disease 
progression, initiation of a new therapy for mCRPC (clin-
ical progression) or first occurrence of an SSE.
Symptomatic skeletal-related events
Time to the first occurrence of an SSE will be defined as 
the time from randomisation to documentation of any of 
the following: (1) use of external beam radiation therapy 
to relieve bone pain, (2) occurrence of new symptom-
atic pathological bone fractures excluding asymptomatic 
compression fractures, (3) known spinal cord compres-
sion, (4) change in antineoplastic therapy to treat bone 
pain or (5) surgical intervention to treat bone pain. This 
information will be determined through adverse event 
(AE) recordings, concomitant medication and treatment 
reviews, and patient medical record reviews.
Progression of pain, degree of pain and opiate use
Analgesic or opiate use will be assessed using the Brief 
Pain Inventory-Short Form (BPI-SF), the WHO Analgesic 
Scale and medical record review at entry with a lead-in 
period of <28 days. The WHO Analgesic Scale will be 
completed every three cycles (and confirmed by medical 
review), with the BPI-SF administered every three cycles 
until cycle 24 and annually thereafter.
Immune status, inflammation, energy metabolism and androgen 
metabolism
Fasted serum, plasma and buffy coat samples (26 mL per 
visit) and first-void urine will be collected (with 4 mL of 
urine aliquots stored) at cycles 0, 6, 12 and 24. Serum 
and plasma aliquots will be used to interrogate a panel 
of markers associated with immune function and inflam-
mation, such as interleukin (IL1β, IL-2, IL-6), tumour 
necrosis factor-α, adiponectin and C reactive protein. 
Energy metabolism will be investigated through markers 
including serum insulin, plasma glucose, C-peptide and 
IGF-1. Androgen metabolism will be explored through 
biomarkers including testosterone, dihydrotestosterone, 
androstenedione, dehydroepiandrosterone, 17-hydroxy-
progesterone, 17-hydroxypregnenolone, sex hormone 
binding globulin and progesterone using mass spectrom-
etry. The study is funded to analyse immune, inflamma-
tion, energy metabolism markers at the four collection 
time points, and androgen metabolism markers at cycles 
0 and 6. Samples will be stored in regional biorepositories 
across the globe throughout the trial in −80°C biomed-
ical freezers prior to batch analyses at the completion of 
the trial, for all patients who provided consent for this to 
occur at randomisation.
Physical function
Muscle strength will be assessed using a one-repetition 
maximum (1RM) test for chest press, leg press, seated 
row and/or leg extension, depending on the loca-
tion and severity of any bone metastases (table 3),9 11 23 
recorded in kilograms. Functional performance will be 
assessed through the 400 m walk test, recording time 
to completion (in seconds) with heart rate maximum 
(HRmax), heart rate average (HRavg) and heart rate 
recovery (HRR) quantified. Aerobic fitness will be 
assessed through a medically supervised CPET to deter-
mine patient VO2 peak (LO2/min and mlO2kg/min) and 
maximum workload (Watts) during a successful CPET 
(RPE ≥9, using the 10-point Borg Scale).24 Physical func-
tion assessments are performed every three to six cycles 
across the 2-year on-trial period as previously described 
(table 1).2 10
Quality of life
Quality of life is measured through questionnaires every 
three cycles, including the Functional Assessment of 
Table 2 Criteria for the establishment of disease 
progression following randomisation
Source Criterion
Bone scan Appearance of ≥2 new lesions on 
bone scan, for bone scans that are 
completed >12 weeks following 
randomisation.
CT/MRI scans ≥20% increase in the sum of lesion 
diameters, taking the reference as the 
smallest sum on study. In addition to this 
relative increase by 20%, the sum must 
also demonstrate the following:
 ► an absolute increase>5 mm, OR
 ► the appearance of one or more new 
lesions, OR
 ► unequivocal progression of baseline 
non-measurable lesions.
mCRPC therapy 
initiation
Development of an indication for 
initiating a therapy for mCRPC after 
randomisation, including but not 
limited to, abiraterone, enzalutamide, 
chemotherapy or radiation therapy.
Symptomatic 
skeletal events
Development of a symptomatic skeletal-
related event that must be attributable to 
disease.
Progression will be defined based on Prostate Cancer Working 
Group 3 (PCWG-3) and Response Evaluation Criteria in Solid 
Tumours (RECIST) 1.1 as all other lesions, including small 
lesions (longest diameter <10 mm or pathological lymph nodes 
10 to <15 mm short axis) as well as truly non-measurable lesions. 
All non-measurable lesions will be recorded at baseline. If patients 
have measurable disease, there must be overall worsening in 
non-measurable disease such that the overall tumour burden has 
increased substantially. The designation of disease progression 
solely on the basis of change in non-measurable disease in the 
face of stable disease or partial response of the measurable 
disease is extremely rare.
mCRPC, metastatic castrate-resistant prostate cancer; CT, 
computed tomography; MRI, magnetic resonance imaging.
9Newton RU, et al. BMJ Open 2018;8:e022899. doi:10.1136/bmjopen-2018-022899
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Cancer Therapy-G; Functional Assessment of Chronic 
Illness Fatigue subscale; European Organisation of 
Research and Treatment of Cancer Quality of Life Ques-
tionnaire 30; Expanded Prostate Cancer Index Composi-
tion 26; EuroQOL 5 Dimensions Questionnaire (EQ5D); 
State-Trait Anxiety Inventory, Center for Epidemiologic 
Studies Depression; and Pittsburgh Sleep Quality Index 
questionnaire.
Programme safety
All AEs will be graded according to the National Cancer 
Institute’s Common Terminology Criteria for Adverse 
Events (V.4.0), and will be assessed at every exercise 
testing and training visit. AEs will also be collected in both 
groups once per month by telephone. AE type, severity, 
attribution (disease-related or exercise-related), expect-
edness and timing will be recorded on case report forms. 
Serious adverse events (SAEs) include events that may 
be life-threatening, require and/or prolong inpatient 
hospitalisation, result in persistent or significant disability 
or incapacity, or result in death. AEs expected on-trial 
include bone pain, pathological skeletal fracture, muscu-
loskeletal injury, joint pain, falls and/or muscle soreness. 
All patients regardless of group will require medical clear-
ance following AEs prior to recommencing their exercise 
programme.
Health economics
An economic evaluation will be performed in parallel to 
the trial to assess the health benefits, additional costs and 
potential savings of including exercise therapy as stan-
dard of care for men with mCRPC. This health economics 
protocol will inform the relative value for money of exer-
cise medicine compared with other healthcare inter-
ventions in this patient population and stage of disease. 
Hospital resource consumption and associated costs will 
also be obtained to assess costs for secondary healthcare 
utilisation between the intervention and control groups 
(supervised exercise and self-directed exercise, respec-
tively). All hospital events, including emergency depart-
ment attendances and admissions, outpatient visits and 
procedures, and inpatient admissions for all causes will 
be explored to quantify and identify potential disease-re-
lated (prostate cancer) events, as well as total healthcare 
resource use for all other purposes inclusive of comor-
bidities and other chronic diseases. The cost of providing 
the supervised exercise and self-managed intervention 
will also be quantified. Due to the international distribu-
tion of investigator sites involved in this study, a regional 
(country by country) and global (pooled) analysis will be 
conducted to account for regional differences in health-
care systems, coverage and costs.
Table 3 Exercise prescription for cycle 0 (weeks 1–4), a fully supervised introduction to exercise while incrementally building 
exercise capacity
Period Resistance exercise Aerobic exercise
Cycle 0 (week 1)
  Session 1 1 set × 8RM × 6 exercises 3×30 s at RPE (5), with 90 s recovery
  Session 2 10 min at RPE (4) (with 2 min recovery as needed)
  Session 3 1 set × 12RM × 6 exercises 3 × 30 s at RPE (5), with 90 s recovery
Cycle 0 (week 2)
  Session 1 2 sets × 8RM × 6 exercises 4 × 30 s at RPE (6), with 90 s recovery
  Session 2 10 min at RPE (4) (with 2 min recovery as needed)
  Session 3 2 sets × 120RM × 6 exercises 4 × 30 s at RPE (6), with 90 s recovery
Cycle 0 (week 3)
  Session 1 3 sets × 8RM × 6 exercises 3 × 60 s at RPE (6), with 120 s recovery
  Session 2 15 min at RPE (5) (with 2 min recovery as needed)
  Session 3 3 sets × 12RM × 6 exercises 3 × 60 s at RPE (6), with 120 s recovery
Cycle 0 (week 4–de-load)
  Session 1 2 sets × 8RM × 6 exercises 3 × 30 s at RPE (6), with 90 s recovery
  Session 2 10 min at RPE (4) (with 2 min recovery as needed)
  Session 3 2 sets × 12RM × 6 exercises 3 × 30 s at RPE (6), with 90 s recovery
Additional descriptions 
  INTERVAL-GAP4 prescription provides a gradually incremental introduction to the exercise programme across cycle 0 
(weeks 1–4). This familiarises and prepares patients for their subsequent participation in moderate-to-high load resistance 
exercise, as well as high-intensity interval and moderate-intensity continuous aerobic exercise. This cycle also contains 
a de-load week to increase recovery and promote adaptation prior to progressing into the full prescription. Programme 
intensity is provided through a repetition maximum (RM) and rating of perceived exertion (RPE) system to support exercise 
autoregulation and patient management throughout cancer treatment and disease progression as needed.11
10 Newton RU, et al. BMJ Open 2018;8:e022899. doi:10.1136/bmjopen-2018-022899
Open Access 
Data on health benefits and costs will be appropriately 
adjusted for covariates, such as age, common comorbidi-
ties (eg, diabetes, cardiovascular disease) and body mass 
index. Health benefits will be measured using quality of 
life derived from the EQ5D and converted to a health 
utility scale using regional norms (where possible) to 
derive quality-adjusted life years for cost utility anal-
ysis. Given the duration of this multinational RCT, costs 
associated with health resource use and delivery of the 
supervised exercise intervention will be standardised to 
a common year. Incremental costs and benefits will be 
subsequently estimated and reported as an incremental 
cost effectiveness ratio, which will be bootstrapped25 to 
identify 95% CIs. This will be subsequently used to quan-
tify the probability of whether the intervention is good 
value for money, and the level of risk for patients with 
mCRPC not being ‘better-off’ by receiving supervised 
exercise (ie, the intervention). Deterministic sensitivity 
analysis will be undertaken to identify the main drivers of 
the costs, outcomes and value for money.
Patient programmes
Exercise prescription
Patients assigned to the intervention arm will receive a 
96-week, individualised (ie, based on a needs analysis and 
physical assessment of patient condition and capacity), 
periodised (ie, the systemic organisation of exercise 
variation into microcycles (weekly), mesocycles (monthly) 
and macrocycles (annually)), progressive and autoregu-
lated (ie, patients progress at their own pace based on vari-
ations in health, performance capability, fatigue, recovery 
capacity or scheduling commitments, with adjustments 
made each session according to patients’ capacity on the 
day of exercise training) programme, consisting of struc-
tured resistance exercise and combinations of high-inten-
sity interval training and moderate-intensity continuous 
training aerobic exercise (table 3 and 4). The initial 48 
weeks of the programme (year 1) will be supervised in an 
exercise clinic setting, with a gradual tapered transition 
to self-management, and the subsequent 48 weeks of the 
programme (year 2) will be self-managed with one exer-
cise visit required at the beginning of each cycle (every 
4 weeks). This exercise prescription critically uses perio-
disation to maximise training stimulus and physiological 
adaptation while also reducing the risk of injury, over-
training or staleness,11 26 autoregulation to allow patients 
with advanced mCRPC to self-determine their capabil-
ities at each session collaboratively with the supervising 
clinical exercise physiologist, thereby lowering intensity 
or volume if the patient is fatigued or unwell, or raising 
intensity or volume if the patient is energetic and moti-
vated.11 26 Furthermore, the exercise programme will 
be modified for any patients with mCRPC with bone 
Table 4 Exercise prescription for cycles 1–11 (weeks 5–48): a progressive, periodised and autoregulated programme with de-
load weeks, tapering supervision to self-management
Period Resistance exercise Aerobic exercise
 Cycles 1–11 (week 1) 
  Session 1 4 sets × 8RM × 6 exercises 6 × 60 s at RPE (8), with 120 s recovery
  Session 2 30–40 min at RPE (5) (with 2 min recovery as needed)
  Session 3 4 sets × 12RM × 6 exercises 6 × 60 s at RPE (8), with 120 s recovery
 Cycles 1–11 (week 2) 
  Session 1 4 sets × 6RM × 6 exercises 6 × 30 s at RPE (9), with 90 s recovery
  Session 2 30–40 min at RPE (6) (with 2 min recovery as needed)
  Session 3 4 sets × 10RM × 6 exercises 6 × 30 s at RPE (9), with 90 s recovery
 Cycles 1–11 (week 3) 
  Session 1 3 sets × 8RM × 6 exercises 6 × 60 s at RPE (8), with 120 s recovery
  Session 2 30–40 min at RPE (5) (with 2 min recovery as needed)
  Session 3 3 sets × 12RM × 6 exercises 6 × 60 s at RPE (8), with 120 s recovery
 Cycles 1–11 (week 4–de-load) 
  Session 1 2 sets × 6RM × 6 exercises 4 × 30 s at RPE (6), with 90 s recovery
  Session 2 30–40 min at RPE (4) (with 2 min recovery as needed)
  Session 3 2 sets × 10RM × 6 exercises 4 × 30 s at RPE (6), with 90 s recovery
 Additional descriptions 
  INTERVAL-MCRPC prescription provides a periodised, progressive and individually tailored programme consisting of 
moderate-to-high load resistance exercise, combined with high-intensity interval and moderate-intensity continuous aerobic 
exercise. Each cycle contains a de-load week to increase recovery and promote adaptation. Programme intensity is provided 
through a repetition maximum (RM) and rating of perceived exertion (RPE) system to support exercise autoregulation 
throughout cancer treatment and disease progression as needed.11
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metastases depending on the size and location of metas-
tases (table 5), performed individually or in small groups 
(of up to 4–6 patients per session).
Resistance exercise intensity is prescribed using the 
repetition maximum (RM) method, which is monitored 
and adjusted throughout the programme, with weight 
increased or decreased as the patient becomes stronger 
or weaker (ie, 8RM refers to the highest amount of weight 
a patient can lift eight times per set). Resistance training 
repetitions will not be performed to the point of neuro-
muscular failure, but rather the set will be ceased 1–2 
repetitions short of the patient being unable to complete 
a repetition. Performing resistance training sets to neuro-
muscular failure are unlikely to provide additional benefit 
in non-athlete populations.27
Aerobic exercise intensity is prescribed using the RPE 
method, where aerobic ergometer resistance or speed 
will be adjusted to elicit the target RPE throughout the 
trial. A confirmatory, supervised aerobic assessment—
the constant load test (CLT)24—will be conducted at the 
start of each cycle to monitor aerobic fitness progression 
across the exercise programme including the self-man-
agement period. The CLT is a short, 3 min submax-
imal exercise test performed on a cycle ergometer at a 
preset workload (70% of achieved CPET workload at 
the screening visit), with a graded 4 min warm-up and 
active 3 min unloaded cool-down (ie, 10 min total). This 
CLT workload established at baseline remains constant 
(unchanged) throughout the trial and is used to assess 
programme effectiveness with HRmax, HRavg, HRR and 
RPE recorded. Impact exercise is excluded from the exer-
cise prescription for all patients as it is a contraindication 
for patients with bone metastases, comprising over 80% 
of patients with mCRPC.
Behavioural support
Patients assigned to the supervised exercise arm will 
also receive behavioural support to help promote 
programme adherence and compliance when tapering 
to self-management. Behavioural support is provided in 
text message format, the overarching focus of which will 
be to increase perceived control in task-specific exercises 
and assist patients with overcoming individual barriers 
to exercise, rooted in the social cognitive theory and 
the theory of planned behaviour constructs.28–30 The level 
of behavioural support provided will increase as patient 
self-management increases, providing one text per week 
(cycle 0), two texts per week (cycles 1–8), three texts per 
week (cycles 9–11) and five texts per week (cycles ≥12). 
Some text messages will ask patients to provide a response 
in a return text message to heighten patient engagement.
Psychosocial support
Psychosocial support will be provided to all patients in 
the trial. Participants will be given a digital or mailed 
newsletter of two to three pages each month, to provide 
education and information on topics relevant for men 
with advanced prostate cancer, including, but not limited 
to, staying healthy, lifestyle behaviours, goal setting, 
managing fatigue, bone health, side effects of treatment, 
managing side effects, depression, social support, pain 
management, sexual intimacy, cognitive changes and 
gaining control.
Self-directed exercise group (control)
Patients randomised to the self-directed exercise group 
will receive the psychosocial support described above. 
In addition, these patients will also be provided with the 
current American College of Sports Medicine guidelines 
for physical activity for cancer survivors31 32 and print 
information on how to pursue a self-directed exercise 
programme.
This self-directed exercise strategy is being employed 
as it would be unethical to ask men with advanced pros-
tate cancer to abstain from exercise for a 2-year period, 
owing to the documented health benefits of exercise in 
patients with prostate cancer with early-stage disease. 
Similarly, this trial uses a single-blinded study design 
where it is not possible to blind patients to the interven-
tion, and given recruited patients are at the end stage of 
life the ability to provide supervised exercise to control 
patients after trial completion to optimise patient reten-
tion is not an option. Thus, it is felt the provision of 
printed material for self-directed exercise will assist with 
patient retention for men randomised to the control 
arm, who are free to exercise as much or as little as they 
like.
There is considerable contrast in the effectiveness of 
a supervised programme pursued in an exercise clinic 
versus home-based and self-directed formats; thus, we 
believe this design will differentiate the benefits of the 
exercise intervention for the primary and secondary 
outcomes and maintain interventional fidelity in the trial. 
Table 5 Modular, multimodal exercise programming for 
patients with mCRPC with known bone metastases across 
resistance, aerobic and flexibility training based on lesion 
sites9 11 22
Metastases 
site
Resistance Aerobic Flexibility
Upper Trunk Lower WB NWB Static
Pelvis √* √ √† √ √‡
Lumbar 
spine
√* √† √ √‡
Thoracic 
spine/ribs
√* √† √ √ √‡
Proximal 
femur
√* √ √† √ √‡
All regions √* √† √ √‡
*Exclusion of shoulder flexion/extension/abduction/adduction—
inclusion of elbow flexion/extension.
†Exclusion of hip extension/flexion—inclusion of knee extension/
flexion.
‡Exclusion of spine/flexion/extension/rotation.
√, target exercise region; mCRPC, metastatic castrate-resistant 
prostate cancer; NWB, non-weight bearing (eg, cycling); WB, 
weight bearing (eg, walking).
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To date, research into unsupervised exercise programmes 
in cancer populations has shown limited effectiveness.33–35
statistical considerations
Analysis will be performed using an intention-to-treat 
approach,36 powered to detect an HR of 0.78 for OS 
between patients randomised to the two treatment arms. 
Given a total enrolment period of 36 months, an on-trial 
period of 24×4 week cycles, a minimum of 36 months of 
follow-up after the on-treatment period; survival time 
following an exponential distribution; and a median OS 
of 33.5 months in the self-directed exercise arm, the esti-
mated sample size required to detect an HR of 0.78 with 
80% power at significance level of 0.05 is 824 (ie, 412 men 
in each arm). Accounting for up to 5% of patients with 
missing data on OS, we aim to enrol 866 men (ie, 433 men 
in each arm). Four interim analyses will be performed: 
feasibility (completed in 2016), intervention effective-
ness (first 15% of patients following the six cycles using 
leg extension strength and 400 m walk test data), efficacy 
(first 50% of patients following death to investigate OS) 
and accrual assessment (quarterly analysis).
trial management
INTERVAL-GAP4 has several levels of management to 
ensure the trial is appropriately governed and opera-
tional. The study protocol was established through a 
Protocol Development Working Group with guidance 
from a Steering Committee and Research Advisory 
Committee, each independent from each other, with glob-
ally recognised leaders in clinical and academic contexts 
pertaining to prostate cancer. Operationally, the INTER-
VAL-GAP4 trial is overseen by the Steering Committee 
and comanaged by the ECC (Exercise Medicine Research 
Institute, Edith Cowan University, Australia), the SCC 
(Department of Urology, UCSF, USA) and the Global 
Project Manager (Global Action Plan, Movember Foun-
dation, Australia), with guidance from the Research 
Advisory Committee. The trial also has a Protocol Amend-
ment Review Committee to continually evaluate protocol 
performance and review or approve proposed site-spe-
cific, investigator-led substudies.
INTERVAL-GAP4 has a Data Safety and Monitoring 
Board (DSMB) to oversee the data monitoring of the trial, 
and to monitor the safety of patients enrolled in the trial, 
which is completely independent of all other governing 
committees and site investigators. The trial also has a 
Medical Monitor Team consisting of several urologists and 
medical oncologists in Canada, UK and USA. The SCC 
oversees site training, enrolment of patients (including 
randomisation), study databases, clinical data collection 
and data auditing, behavioural and psychosocial support 
programmes, country-specific translations, AE and SAE 
reporting, liaison with the Medical Monitors and DSMB, 
and implementation of central data collection software 
(REDCap, Vanderbilt University, Nashville, USA). The 
ECC oversees site training of exercise physiologists and 
professionals pertaining to exercise programming and 
supervision of patients with advanced prostate cancer; 
oversees exercise testing and training, and delivery of 
the INTERVAL-GAP4 prescription; and manages exercise 
data collection, auditing and implementation of the exer-
cise management software (Physitrack, Brighton, UK). 
All data entered into REDCap and Physitrack are de-iden-
tified (ie, using patients’ study identifier), with all forms 
uploaded to REDCap de-identified (ie, all identifiable 
information is redacted).
Patient and public involvement
Movember Foundation is a charitable organisation advo-
cating for improved outcomes for men with prostate 
cancer. As the funder of this global trial, with extensive 
consumer representative networks (ie, patients, their 
families and their carers) across the globe, the organi-
sation is uniquely positioned to represent the views and 
experiences of consumers in Australia, Canada, UK and 
the USA (among others) who have engaged with Movem-
ber’s activities over the past 15 years. This unique view-
point and experience have been used to ensure that 
the study protocol engages participants in a respectful, 
ethical and impactful way, while addressing the needs of 
patients with mCRPC. Movember Foundation, with their 
consumer representative networks, will also facilitate the 
delivery of this study, by providing assistance with patient 
recruitment and support, as well as the translation and 
dissemination of the research findings to community 
members, patients and cancer support groups. In addi-
tion, the research team of this study protocol includes 
urologists and medical oncologists who work with the 
target population on a daily basis, from which these clini-
cians have used patient priorities, patient experience and 
patient preferences to help inform the development of 
the research questions and outcome measures. Lastly, the 
broader research team has conducted research studies in 
exercise and prostate cancer involving large quantities of 
participants over the course of the past 20 years, providing 
feedback to investigators to help design better exercise 
oncology clinical trials. This sizeable patient interaction 
across the clinical and community landscape has contrib-
uted substantially to the design of this project.
EthICs And dIssEMInAtIon
Ethics approval was first obtained at Edith Cowan Univer-
sity (ID: 13236 NEWTON), with a further 10 investigator 
sites in Australia, Canada, Europe, UK and USA since 
receiving site-specific human research ethics approval, 
prior to site activation and recruitment commencement. 
All future investigator sites joining the INTERVAL-GAP4 
study are required to obtain site-specific human research 
ethics committee approvals, undergo site-based educa-
tion and training, and receive a site initiation visit prior 
to opening for recruitment. Future amendments to 
the protocol and associated documentation, if any, will 
be deliberated and approved by the Protocol Amend-
ment Review Committee, followed by submission to and 
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approval of the Steering Committee. Approved amend-
ments will be subsequently distributed to individual site 
investigators for submission to their human research 
ethics committees by the SCC.
Validation of exercise as medicine and its mechanisms 
of action will create evidence to change clinical practice. 
Accordingly, outcomes of this RCT will be published in 
international, high-quality, peer-reviewed journals, and 
presented at national and international conferences 
or research meetings. Outcomes of this study will also 
be delivered to community and consumer-led forums, 
and will be presented at local hospital departments and 
university seminars. Lastly, evidence derived from this 
RCT will be inserted into updated clinical exercise and/
or medical guidelines and position statements within 
national and international governing bodies.
dIsCussIon
Preliminary evidence supports the potential beneficial 
role of exercise for prostate cancer survival. Exercise 
has potential as a low-toxicity adjuvant medicine that 
can be combined with standard cancer therapies to 
improve patient outcomes,11 with the exciting possibility 
of improving OS.1 Data from observational epidemio-
logical studies provide a convincing body of evidence 
to suggest a considerable survival benefit from habitual 
physical activity prediagnosis and postdiagnosis in men 
with prostate cancer.4 5 37–40 While these studies provide 
useful associations, they cannot infer or establish a causal 
relationship, and are subject to bias due to measurement 
error, unmeasured and residual confounding, reverse 
causation, and self-selection. Consequently, there is a need 
for RCTs to directly evaluate the relationship between 
exercise (herein delivered as a tailored 2-year exercise 
prescription) and OS in men with prostate cancer.1 11 The 
INTERVAL-GAP4 protocol outlined in this paper aims to 
achieve this ambitious undertaking, and we hypothesise 
that a tailored, partially supervised, structured exercise 
intervention will deliver greater benefits than incidental 
or self-managed physical activity. This study is the first 
worldwide to explore the impact of exercise on OS in 
prostate cancer.
If it is demonstrated that this exercise intervention 
results in a clinically meaningful improvement in patient 
survival, then such exercise prescriptions can be immedi-
ately implemented worldwide, providing benefits to men 
with advanced prostate cancer. Further elucidation of 
the mechanisms by which exercise provides this survival 
benefit may inform the development of future thera-
peutic agents as well as improve the synergistic provision 
of exercise prescriptions in combination with existing 
therapies including chemotherapy, radiation therapy, 
enzalutamide and abiraterone.
Following protocol development and endorsement 
by the Steering Committee and Research Advisory 
Committee, the INTERVAL-GAP4 trial was launched in 
December 2015. Following trial launch, a pilot site in 
Perth, Western Australia (Edith Cowan University) was 
chosen to demonstrate protocol feasibility across the 
inaugural year (recruiting from March 2016 to November 
2016), whereby the study protocol went through several 
iterations to enable minor amendments (from version 1 to 
version 4) under the guidance of a Protocol Amendment 
Review Committee, with Steering Committee oversight. 
Following the established feasibility and demonstration 
of the study protocol (with 10 patients randomised at the 
pilot site in year 1), along with the concurrent establish-
ment of each trial coordination centre (SCC, ECC), inves-
tigator sites worldwide began to open for recruitment in 
January 2017 in a staggered process, with six sites open 
midyear (July 2017) and a further five sites open by the 
end of the year (December 2017). The remaining inves-
tigator sites are due to open within the subsequent 12 
months (December 2018) and additional sites are being 
considered. This study protocol conforms to the Stan-
dard Protocol Items: Recommendations for Interven-
tional Trials and the Consensus on Exercise Reporting 
Template statements for RCTs and exercise reporting 
requirements.41 42
ConClusIons
Exercise is rapidly evolving as an emerging and provoca-
tive therapy in oncology, with excellent promise to meet 
the broad and magnified needs of patients with advanced 
prostate cancer. In particular, exercise has the potential 
to delay disease progression and extend patient survival 
through numerous potential systemic and localised, 
mechanical and non-mechanical mechanisms. INTER-
VAL-GAP4 will be the first RCT to definitively examine if 
supervised aerobic and resistance exercise increases OS 
among men with mCRPC compared with self-directed 
physical activity.
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